Render Target: STATIC
Render Timestamp: 2025-03-14T11:31:10.770Z
Commit: a619ae74f66dae0f27639e88da12bcf600e46428
XML generation date: 2025-03-07 13:19:50.972
Product last modified at: 2025-01-01T09:06:27.515Z
Cell Signaling Technology Logo
1% for the planet logo
PDP - Template Name: Monoclonal Antibody
PDP - Template ID: *******c5e4b77
R Recombinant
Recombinant: Superior lot-to-lot consistency, continuous supply, and animal-free manufacturing.

NMI (F6F5E) Rabbit mAb #25630

Filter:
  • WB
  • IP

    Supporting Data

    REACTIVITY H
    SENSITIVITY Endogenous
    MW (kDa) 40
    Source/Isotype Rabbit IgG
    Application Key:
    • WB-Western Blotting 
    • IP-Immunoprecipitation 
    Species Cross-Reactivity Key:
    • H-Human 

    Product Information

    Product Usage Information

    Application Dilution
    Western Blotting 1:1000
    Simple Western™ 1:50 - 1:250
    Immunoprecipitation 1:50

    Storage

    Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

    Protocol

    Specificity / Sensitivity

    NMI (F6F5E) Rabbit mAb recognizes endogenous levels of total NMI protein. This antibody does not cross-react with IFI35 protein.

    Species Reactivity:

    Human

    Source / Purification

    Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human NMI protein.

    Background

    N-Myc and STAT interactor (NMI) is an interferon inducible protein that functions as a transcriptional regulator (1). Research studies have demonstrated that intracellular pools of NMI, in complex with interferon-induced 35 kDa protein (IFI35), negatively regulate innate immune antiviral signaling by blunting type I interferon production (2,3). NMI has been shown to interact with a variety of transcription factors that play a role in tumorigenesis, including N-myc, c-Myc, BRCA1, STAT1, STAT3, STAT5, and NF-κB (4-8). Its downregulation has been linked to enhanced tumor growth and invasiveness in lung and breast cancers, respectively (9,10). Conversely, elevated NMI expression in glioblastoma correlates with poor prognosis, suggesting that NMI’s role in cancer is tumor-dependent (11). Additional studies indicate that NMI can be used as a biomarker for immune cell infiltration and immune checkpoint expression in tumor tissue (12). 
    For Research Use Only. Not For Use In Diagnostic Procedures.
    Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
    All other trademarks are the property of their respective owners. Visit our Trademark Information page.